ADVERTISEMENT
Expert Roundtable: BEACON Trial Yields Novel Therapy for BRAFV600E–Mutated CRC
08/13/2019
In a discussion panel hosted by Axel Grothey, MD, at the ESMO World Congress on Gastrointestinal Cancer 2019, Josep Tabernero, MD, PhD, and Scott Kopetz, MD, PhD, FACP, discussed the findings and clinical significance of the phase 3 BEACON CRC clinical trial, in which the combination therapy of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic CRC.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement